Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Operational Fixes At Cipla But All Eyes On Generic Advair

Executive Summary

Cipla is implementing certain operational fixes and tweaks in its European and emerging markets businesses as it emerges from a weak fourth quarter that saw profits fall sharply, but limited visibility around the firm's Advair generic in certain key markets appeared to fluster some investors.

You may also be interested in...



Cipla Trims Staff At Indian Plant As It Eyes Costs

The rumor mill has it that Cipla has effected significant staff cuts at its Pithampur facility in India, as it keeps a sharp eye on costs and drives efficiencies at its manufacturing operations. But the company isn’t saying much except that it routinely conducts "performance-based reviews."

Cipla Evaluates US Portfolio Tucks, Generic Advair Studies Progress

Alongside a build-up in the US, Cipla is keeping a sharp eye on its “profitability profile” in this market and expects to rationalize products that don’t fit the bill. But it remains on track to establishing a respiratory franchise in key regulated markets, with generic Advair studies moving forward in the US.

Cipla Revs Up In US, Newer Markets To Cushion Against Volatility

US scale-up plans, cost optimization and a deeper push in certain other markets to garner volumes and as a buffer against volatility were some of the key strategies discussed by Cipla’s CEO at the recent J.P. Morgan Healthcare Conference in San Francisco.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC065271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel